Exelixis, Inc. (NASDAQ: EXEL): COMETRIQ Availability in the U.S.

By smallcapbiotech

January 25, 2013

Comments Off on Exelixis, Inc. (NASDAQ: EXEL): COMETRIQ Availability in the U.S.

Exelixis, Inc. (NASDAQ: EXEL) is a biopharmaceutical company committed to developing and commercializing small molecule therapies for the treatment of cancer. Exelixis announced on Thursday the commercial availability of COMETRIQ® (cabozantinib) for the treatment of patients with progressive, metastatic medullary thyroid cancer approved by FDA on November 29, 2012. COMETRIQ (cabozantinib) is being distributed exclusively …Read More

Acadia Pharmaceuticals (ACAD): Elected BOD Member

By smallcapbiotech

January 25, 2013

Comments Off on Acadia Pharmaceuticals (ACAD): Elected BOD Member

Acadia Pharmaceuticals (ACAD) is a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders. Acadia’s lead product candidate, pimavanserin, is in Phase III development . Pimavanserin is projected to be a potential first-in-class treatment for Parkinson’s disease psychosis. On January 18, 2013, Acadia’s Board of …Read More

Threshold Pharmaceuticals (THLD): Merck KGaA Initiated the Global Phase 3 MAESTRO Study

By smallcapbiotech

January 25, 2013

Comments Off on Threshold Pharmaceuticals (THLD): Merck KGaA Initiated the Global Phase 3 MAESTRO Study

Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) is a clinical stage biopharmaceutical company focused on the discovery and development of cancer therapeutics based on a novel and powerful approach of targeting tumor hypoxia. THLD today announced that Threshold’s partner Merck KGaA, Darmstadt, Germany, through its division Merck Serono, initiated the global Phase 3 MAESTRO study assessing the …Read More

NuPathe Inc. (NASDAQ: PATH): FDA Approval of the Zecuity

By smallcapbiotech

January 17, 2013

Comments Off on NuPathe Inc. (NASDAQ: PATH): FDA Approval of the Zecuity

NuPathe Inc. (PATH) today announced that the U.S. Food and Drug Administration (FDA) has approved Zecuity™ (sumatriptan iontophoretic transdermal system) for the acute treatment of migraine with or without aura in adults. Zecuity is a single-use, battery-powered patch that actively delivers sumatriptan, the most widely prescribed migraine medication, through the skin. Zecuity provides relief of …Read More

pSivida Corp. (NASDAQ:PSDV): Authorization to ILUVIEN in Spain

By smallcapbiotech

January 17, 2013

Comments Off on pSivida Corp. (NASDAQ:PSDV): Authorization to ILUVIEN in Spain

pSivida (NASDAQ: PSDV) is a leading provider of miniaturized, sustained-release drug delivery products and is continuing the evolution of these systems. PSDV proprietary technologies enable to achieve highly focused, long-term delivery of therapeutics. Company has developed three of the only four products approved by either the US or EU for the long-term, sustained-released delivery of …Read More

Neuralstem (CUR): FDA Approval for the Phase 1 Trial of NSI-566

By smallcapbiotech

January 14, 2013

Comments Off on Neuralstem (CUR): FDA Approval for the Phase 1 Trial of NSI-566

Neuralstem’s (CUR) patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. In August 2012, Neuralstem completed the final surgery of an FDA-approved Phase I NSI-566 …Read More

iBio, Inc. (IBIO): Speculative Flu Vaccine Stock

By smallcapbiotech

January 13, 2013

Comments Off on iBio, Inc. (IBIO): Speculative Flu Vaccine Stock

Sophisticated traders must take a look at iBio, Inc. (IBIO) as it seems that company has been overlooked as a solid player on the flu market. The high level of flu cases being reported across all states in the USA and Europe. Only in New York state a flu epidemic has hit more than 19,000 …Read More

Telik, Inc. (TELK): Telintra Granted Orphan Drug Designation by the FDA

By smallcapbiotech

January 13, 2013

Comments Off on Telik, Inc. (TELK): Telintra Granted Orphan Drug Designation by the FDA

Telik, Inc. (TELK) is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer. Telik’s product candidates are: TELINTRA® (TLK199) is in Phase 2 clinical development for myelodysplastic syndrome, and severe chronic idiopathic neutropenia TELCYTA® (TLK286) is a cancer cell-activated chemotherapeutic that has shown clinical activity in Phase …Read More

Rosetta Genomics (ROSG): Published Study of microRNA characteristics of CUP tumors

By smallcapbiotech

January 9, 2013

Comments Off on Rosetta Genomics (ROSG): Published Study of microRNA characteristics of CUP tumors

Rosetta Genomics is a leading molecular diagnostics company advancing molecular tests based on its proprietary microRNAs, and platform technologies. Following the launch of five cancer tests since the beginning of 2009, the Company is now working to develop additional tests in the cancer realm and in other fields. Rosetta Genomics today announced results from a …Read More

Delcath Systems, Inc. (DCTH): Stock for 2013?

By smallcapbiotech

January 9, 2013

Comments Off on Delcath Systems, Inc. (DCTH): Stock for 2013?

Delcath (NASDAQ: DCTH) is a development-stage, specialty pharmaceutical and medical device company focused on oncology. Company is researching breakthroughs in regional chemotherapies with the goal of improving clinical outcomes and potentially reducing drug-related adverse events. At glance: Commercial stage company focused on oncology Proprietary CHEMOSAT delivery systems allow unique whole organ therapy for the liver …Read More